DCM
MRTX

Dupont Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Dupont Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,909
Closed -$86.5K – 1290
2022
Q4 		$86.5K Buy
+1,909
New +$124K ﹤0.01% 983
2022
Q1 		– Sell
-776
Closed -$114K – 1818
2021
Q4 		$114K Buy
+776
New +$120K ﹤0.01% 1270
2020
Q4 		– Sell
-3,070
Closed -$510K – 1432
2020
Q3 		$510K Buy
+3,070
New +$420K 0.01% 748

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Dupont Capital Management's MRTX Position: Q1 2023 in Review

Dupont Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2023, closing a stake of 1,909 shares — an estimated $86.5K sold.

Dupont Capital Management first reported a position in MRTX in Q3 2020 and held it in 3 quarters. The position peaked at $510K in Q3 2020. 221 funds tracked by Wall St. Rank hold MRTX as of Q1 2023.

  • Dupont Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Dupont Capital Management sold 1,909 Mirati Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $86.5K.
  • Dupont Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Dupont Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $510K in Q3 2020.
  • 221 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.